A leading British medical company, Halo Therapeutics, announced its plans to start the second stage of clinical trials for a new nasal COVID-19 drug, Sky News reported on Tuesday.
The new medicine is effective against all mutated COVID-19 variants including the UK, South African, and Brazilian strains.
The research team included scientists from Bristol University to develop various COVID-19 medicines in the light of the third wave of the virus.
The team succeeded in finding the "molecule" that can negatively impact the protein's structure preventing it from spreading in the human body.
Also, they managed to detect the "linoleic acid" that can turn the virus into an ineffective form.
Also, the researchers found that the new medicine is effective with other COVID-19 drugs such as Remdesivir, according to Science Magazine.
Professor Christiane Berger-Schaffitzel told the journal: "Our vision is that at the first sign of the disease, whether you come into contact with someone has COVID-19 or you have early symptoms, you would self-medicate at home to stop the virus in its tracks and prevent you from getting ill."
Follow the latest news on Google News
